Various Applications of Tofacitinib and Ruxolitinib in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective

October 2022 in “ Dermatology practical & conceptual ”

Sara Sadeghi, Azadeh Goodarzi

tofacitinib ruxolitinib Janus kinase inhibitors JAKi alopecia areata psoriasis vulgaris psoriatic arthritis atopic dermatitis vitiligo hidradenitis suppurativa lichen planus pyoderma gangrenosum Xeljanz Opzelura

TLDR Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

The review article discusses the efficacy and safety of Janus kinase inhibitors (JAKi), specifically tofacitinib and ruxolitinib, in treating various autoimmune disorders, including alopecia areata (AA), psoriasis vulgaris (PV), psoriatic arthritis (PsA), atopic dermatitis (AD), vitiligo, hidradenitis suppurative (HS), lichen planus (LP), and pyoderma gangrenosum (PG). The review was based on a comprehensive search of PubMed and Google Scholar for meta-analyses, systematic reviews, clinical trials, and case studies, excluding duplicated data and animal or in vitro studies. The results from the articles reviewed indicated that both tofacitinib and ruxolitinib have beneficial effects in treating the mentioned autoimmune disorders and have acceptable safety profiles. Physicians are advised to consider the risks and benefits of these treatments for each specific condition.

View this study on dpcj.org →

Discuss this study in the Community →

Cited in this study

5 / 5 results

research A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata

40 citations , June 2021 in “Clinical, cosmetic and investigational dermatology”

JAK inhibitors show promise in effectively treating hair loss from alopecia areata.

research Benefit and Risk Profile of Tofacitinib for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis

54 citations , October 2019 in “Journal of the European Academy of Dermatology and Venereology”

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

research Tofacitinib for the Treatment of Lichen Planopilaris: A Case Series

79 citations , September 2018 in “Dermatologic therapy”

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

research JAK Inhibitors in Dermatology: The Promise of a New Drug Class

355 citations , April 2017 in “Journal of the American Academy of Dermatology”

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

research Overview of Alopecia Areata

110 citations , December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings”

Alopecia areata is a genetic and immune-related hair loss condition that is often associated with other autoimmune diseases and does not typically cause permanent damage to hair follicles.